GlassScriptPhysician profile
Gary Steven Rosenbaum
NPI 1437261385
$3,613.59
in general payments reported to CMS, 2019-2025
28 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $261 · 2021: $676 · 2022: $240 · 2023: $645 · 2024: $588 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.81 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,094.39 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $513.12 | 2019-2024 | Xifaxan |
| Romark Laboratories, Lc | $345.68 | 2019 | |
| Janssen Biotech, INC. | $261.65 | 2019-2025 | Stelara, Symtuza, Simponi |
| Abbvie INC. | $175.22 | 2019-2024 | Mavyret |
| Redhill Biopharma INC. | $145.80 | 2020-2024 | Talicia |
| Janssen Products, LP | $131.44 | 2021 | |
| Phathom Pharmaceuticals, INC. | $127.47 | 2024 | Voquezna |
| Comsort, INC | $100.00 | 2019 | |
| Daiichi Sankyo INC. | $74.29 | 2019-2023 | Injectafer |
| Allergan, INC. | $67.92 | 2019-2020 | |
| Pfizer INC. | $55.04 | 2023 | |
| Braintree Laboratories, INC. | $51.89 | 2021-2023 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $47.94 | 2021 | |
| Solventum Corporation | $43.87 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $42.21 | 2025 | Nuzyra |
| Intercept Pharmaceuticals, INC. | $40.46 | 2021-2022 | |
| Ardelyx, INC. | $40.42 | 2023 | Ibsrela |
| Qol Medical, LLC | $40.25 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $35.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Melinta Therapeutics, LLC | $27.17 | 2023 | Orbactiv, Kimyrsa, Vabomere |
| Exact Sciences Corporation | $25.62 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $24.96 | 2023 | Rebyota |
| Concordia Pharmaceuticals INC. | $21.51 | 2019 | |
| Vyera Pharmaceuticals, LLC | $17.84 | 2019 | |
| Viiv Healthcare Company | $16.99 | 2024 | Rukobia |
| Gilead Sciences, INC. | $16.47 | 2024 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Rosenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.